127 related articles for article (PubMed ID: 11683518)
1. The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery.
Schmidt DT; Rühlmann E; Waldeck B; Branscheid D; Luts A; Sundler F; Rabe KF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Oct; 364(4):314-20. PubMed ID: 11683518
[TBL] [Abstract][Full Text] [Related]
2. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
[TBL] [Abstract][Full Text] [Related]
3. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies.
O'Donnell M; Garippa RJ; Rinaldi N; Selig WM; Simko B; Renzetti L; Tannu SA; Wasserman MA; Welton A; Bolin DR
J Pharmacol Exp Ther; 1994 Sep; 270(3):1282-8. PubMed ID: 7932180
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal polypeptide (VIP) phase-shifts the rat suprachiasmatic nucleus clock in vitro.
Reed HE; Meyer-Spasche A; Cutler DJ; Coen CW; Piggins HD
Eur J Neurosci; 2001 Feb; 13(4):839-43. PubMed ID: 11207820
[TBL] [Abstract][Full Text] [Related]
5. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
6. Helospectin, induces a potent relaxation of human airways in vitro.
Cardell M; Cardell LO
Peptides; 2001 Sep; 22(9):1359-62. PubMed ID: 11514015
[TBL] [Abstract][Full Text] [Related]
7. Influence of melatonin on bovine pulmonary vascular and bronchial airway smooth muscle tone.
Weekley LB
Clin Auton Res; 1995 Feb; 5(1):53-6. PubMed ID: 7540081
[TBL] [Abstract][Full Text] [Related]
8. Pituitary adenylate cyclase-activating peptide 38 a potent endogenously produced dilator of human airways.
Kinhult J; Andersson JA; Uddman R; Stjärne P; Cardell LO
Eur Respir J; 2000 Feb; 15(2):243-7. PubMed ID: 10706486
[TBL] [Abstract][Full Text] [Related]
9. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis.
O'Donnell M; Garippa RJ; Rinaldi N; Selig WM; Tocker JE; Tannu SA; Wasserman MA; Welton A; Bolin DR
J Pharmacol Exp Ther; 1994 Sep; 270(3):1289-94. PubMed ID: 7932181
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of vascular relaxation and receptor binding by PACAP and VIP.
Huang M; Shirahase H; Rorstad OP
Peptides; 1993; 14(4):755-62. PubMed ID: 8234021
[TBL] [Abstract][Full Text] [Related]
11. Cytosolic Ca2+ responses to sub-picomolar and nanomolar PACAP in pancreatic beta-cells are mediated by VPAC2 and PAC1 receptors.
Yamada H; Watanabe M; Yada T
Regul Pept; 2004 Dec; 123(1-3):147-53. PubMed ID: 15518905
[TBL] [Abstract][Full Text] [Related]
12. Effects of vasoactive intestinal polypeptide on neurones of the rat suprachiasmatic nuclei in vitro.
Reed HE; Cutler DJ; Brown TM; Brown J; Coen CW; Piggins HD
J Neuroendocrinol; 2002 Aug; 14(8):639-46. PubMed ID: 12153466
[TBL] [Abstract][Full Text] [Related]
13. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
14. Distribution of the VPAC2 receptor in peripheral tissues of the mouse.
Harmar AJ; Sheward WJ; Morrison CF; Waser B; Gugger M; Reubi JC
Endocrinology; 2004 Mar; 145(3):1203-10. PubMed ID: 14617572
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma.
Saga T; Said SI
Trans Assoc Am Physicians; 1984; 97():304-10. PubMed ID: 6535346
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
[TBL] [Abstract][Full Text] [Related]
17. Bronchodilating properties of the VIP receptor agonist Ro 25-1553 compared to those of formoterol on the guinea-pig isolated trachea.
Källström BL; Waldeck B
Eur J Pharmacol; 2001 Nov; 430(2-3):335-40. PubMed ID: 11711052
[TBL] [Abstract][Full Text] [Related]
18. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells.
Onoue S; Ohmori Y; Endo K; Yamada S; Kimura R; Yajima T
Eur J Biochem; 2004 May; 271(9):1757-67. PubMed ID: 15096214
[TBL] [Abstract][Full Text] [Related]
20. Relaxation of isolated guinea pig trachea, bronchi and pulmonary arteries produced by vasoactive intestinal peptide (VIP).
Hand JM; Laravuso RB; Will JA
Eur J Pharmacol; 1984 Feb; 98(2):279-84. PubMed ID: 6714311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
